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The transcription factor NF-B plays a central role in the human immunodeficiency virus type 1 (HIV-1)
activation pathway. HIV-1 transcription is also regulated by protein acetylation, since treatment with deacety-
lase inhibitors such as trichostatin A (TSA) or sodium butyrate (NaBut) markedly induces HIV-1 transcrip-
tional activity of the long terminal repeat (LTR) promoter. Here, we demonstrate that TSA (NaBut) synergized
with both ectopically expressed p50/p65 and tumor necrosis factor alpha/SF2 (TNF)-induced NF-B to activate
the LTR. This was confirmed for LTRs from subtypes A through G of the HIV-1 major group, with a positive
correlation between the number of B sites present in the LTRs and the amplitude of the TNF-TSA synergism.
Mechanistically, TSA (NaBut) delayed the cytoplasmic recovery of the inhibitory protein IB. This coincided
with a prolonged intranuclear presence and DNA binding activity of NF-B. The physiological relevance of the
TNF-TSA (NaBut) synergism was shown on HIV-1 replication in both acutely and latently HIV-infected cell
lines. Therefore, our results open new therapeutic strategies aimed at decreasing or eliminating the pool of
latently HIV-infected reservoirs by forcing viral expression.
The persistence of latently human immunodeficiency virus
(HIV)-infected cellular reservoirs, despite prolonged treat-
ment with highly active antiretroviral therapy (HAART), rep-
resents the major hurdle to virus eradication. These latently
infected cells are a permanent source for virus reactivation and
lead to a rebound of the viral load after interruption of
HAART (reviewed in reference 42). Therefore, a greater un-
derstanding of the molecular mechanisms regulating viral la-
tency and reactivation should lead to rational strategies aimed
at purging the latent HIV reservoirs (6). At the cellular level,
two major forms of HIV type 1 (HIV-1) latency have been
described: preintegration latency and postintegration latency
(reviewed in reference 33). Several cell lines selected in vitro
have served as models for studying the latter type of latency. In
these cell lines, production of viral particles can be induced at
the transcriptional level by a variety of agents, including phor-
bol esters and cytokine tumor necrosis factor SF2 (TNF) (16).
Several explanations have been proposed for the low level of
transcription observed during postintegration latency, includ-
ing the following. (i) The first explanation involves the site of
integration of the provirus into the host cell genome and the
cellular chromatin environment at this site (26, 60). (ii) A
second explanation involves the presence of a potentially re-
pressive nucleosome (nuc-1) located immediately downstream
of the HIV transcription start site under latency conditions.
Nuc-1 is remodeled upon activation of the HIV promoter
located in its 5 long terminal repeat (LTR) in response to Tat,
phorbol esters, and deacetylase inhibitors (12, 54, 58). Nuc-1
could pose a unique elongation barrier for the polymerase, and
its remodeling could play a significant role in the transcrip-
tional reactivation of the HIV promoter from latency (re-
viewed in reference 52). (iii) A third explanation involves the
absence of the viral trans-activator Tat, which binds to TAR, an
RNA hairpin loop formed at the 5 termini of all nascent
HIV-1 transcripts (1). (iv) A fourth explanation involves the
presence of mutations in the integrated provirus, including
interruption of the Tat-TAR axis (13, 14). (v) A fifth explana-
tion involves the absence of the inducible transcription factor
NF-B. The enhancer in the U3 region of the LTR contains
two binding sites for NF-B, which plays a central role in the
activation pathway of the HIV-1 provirus. Various studies have
reported that the NF-B-binding sites as well as the NF-B
proteins are critical for LTR promoter activity and important
for optimal HIV-1 replication (reviewed in reference 44). Re-
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cently, West et al. have shown that p65 stimulates transcrip-
tional elongation of the HIV-1 promoter (59).
NF-B is an inducible transcription factor complex that
plays a role in the expression of a variety of genes involved in
immune and inflammatory responses and cell survival (re-
viewed in references 18 and 28). In mammalian cells, there are
five known members of the NF-B/Rel family: p65 (RelA),
c-Rel, RelB, p50, and p52. The most widely studied and most
abundant form of NF-B is a heterodimer of p50 and p65. In
unstimulated cells, NF-B is sequestered in the cytoplasm in
an inactive form through interaction with inhibitory IB pro-
teins including IB, IB, and IBε. Upon activation of
NF-B by various stimuli (including inflammatory cytokines
[TNF and interleukin-1], bacterial lipopolysaccharides, viral
proteins, and mitogens [phorbol esters and UV light]), IBs
are rapidly phosphorylated by a macromolecular IB kinase
complex (22, 27), ubiquitinated, and degraded by the 26S pro-
teasome. The released NF-B then translocates to the nucleus,
where it can activate transcription from a wide variety of pro-
moters, including that of its own inhibitor, IB. The newly
synthesized IB enters the nucleus, enhances NF-B removal
from DNA, and takes it back to the cytoplasm, thus restoring
the inducible cytoplasmic pool of NF-B. Thus, the de novo
expression of IB proteins, which display nucleocytoplasmic
shuttling properties, participates in a negative feedback system
ensuring a transient NF-B transcriptional response (reviewed
in references 28 and 32).
There is now strong evidence that both transcriptional acti-
vation and silencing are mediated through the recruitment of
enzymes that control protein acetylation. Acetylation of spe-
cific lysine residues within nucleosomal histones is closely
linked to chromatin disruption and transcriptional activation in
many genes. Consistent with their role in altering chromatin
structure, many transcriptional coactivators (including GCN5,
CBP/p300, p300/CBP-associated factor [P/CAF], and SRC-1)
possess intrinsic histone acetyltransferase activity that is critical
for their function (reviewed in reference 46). Similarly, core-
pressor complexes include proteins that have histone deacety-
lase (HDAC) activity (reviewed in reference 29). Importantly,
reversible acetylation is also a critical posttranslational modi-
fication of nonhistone proteins, including general and specific
transcription factors, coactivators, nonhistone structural chro-
mosomal proteins, and nuclear import factors. Protein acety-
lation regulates many diverse functions, including DNA bind-
ing, protein-protein interaction, protein stability, and cellular
localization (reviewed in references 3 and 31). Hence, acety-
lation may rival phosphorylation as a mechanism for the trans-
duction of cellular regulatory signals.
In the case of HIV-1, we and others have previously re-
ported ample evidence that viral transcription is regulated by
protein acetylation. We have shown that treatment of latently
HIV-infected cell lines with deacetylase inhibitors [trichostatin
A (TSA), trapoxin, and sodium butyrate (NaBut)] induces viral
transcription and nuc-1 remodeling (54; reviewed in reference
52). Transcriptional activation of the HIV-1 promoter in re-
sponse to TSA has also been demonstrated in ex vivo tran-
siently or stably transfected HIV LTR reporter constructs (12,
26, 30) and on in vitro chromatin-reconstituted HIV-1 tem-
plates (48, 49). Moreover, acetylation of Tat by p300, by
P/CAF, and by human GCN5 is important for its transcrip-
tional activity (7, 30).
To better understand the molecular mechanisms regulating
HIV-1 reactivation from latency, we here extended our studies
on the TSA inducibility of the viral promoter (LTR) and fo-
cused on the functional role of the B sites in this TSA re-
sponse. In this report, we demonstrate that deacetylase inhib-
itors (TSA and NaBut) synergized with both ectopically
expressed p50/p65 and TNF-induced NF-B to activate the
HIV-1 promoter. This synergism required intact B sites and
was observed with LTRs from subtypes A through G of the
HIV-1 group M (major). TSA and NaBut drugs prolonged
TNF-induced NF-B binding to DNA and the intranuclear
presence of p65. Remarkably, a marked delay in the cytoplas-
mic recovery of IB coincided with the prolonged binding
activity and presence of NF-B in the nucleus. Importantly, the
physiological relevance of the TNF-TSA (NaBut) synergism
was shown both on HIV-1 reactivation in a model cell line for
postintegration latency and on HIV-1 replication in the context
of a de novo viral infection. Therefore, our results open new
therapeutic strategies aimed at forcing viral expression and at
contributing, in the presence of an efficient HAART, to a
reduction of the pool of latently HIV-infected cellular reser-
voirs.
MATERIALS AND METHODS
Cell culture. The U1 and SupT1 cell lines were obtained from the AIDS
Research and Reference Reagent Program (National Institute of Allergy and
Infectious Diseases [NIAID], National Institutes of Health [NIH]). The mono-
cytic cell lines U937 (reference no. 85011440) and HL60 (reference no.
98070106) were obtained from the European Collection of Cell Cultures. All cell
lines were grown as reported previously (56).
Plasmid constructs. The plasmids pLTR(1-789)-luc, pLTR(292-789)-luc,
pLTR(1-531)-luc, pLTR(292-531)-luc, and pLTR(345-531)-luc contain the HIV-
1LAI 5 LTR (nucleotides indicated parenthetically) cloned into the reporter
vector pGL2-Basic (Promega). To construct pLTR(345-531)mut B-luc, pLTR
(345-531)-luc was used as substrate for mutagenesis of the two B sites (5-AA
CTCACTTTCCGCTGCTCACTTTCCA-3; the mutations are shown in bold-
face type, and the B sites are underlined on the coding strand) by the
QuikChange site-directed mutagenesis method (Stratagene).
The pLTR(A, B, C1, D, E, F, G, AG)-luc plasmids were previously described
(23).
The plasmids pRSV-p50 and pRSV-p65 were obtained from G. Nabel and N.
Perkins through the AIDS Research and Reference Reagent Program (Division
of AIDS, NIAID, NIH).
Transient transfection and luciferase assays. SupT1 cells were transfected
using the DEAE-dextran procedure as previously described (56). At 20 h post-
transfection, the cells were treated or mock treated with TSA (450 nM when a
single dose was used) (Sigma Chemical Co.), NaBut (5 mM) (Sigma Chemical
Co.), TNF (10 ng/ml; catalog no. 210-TA; R&D Systems) or a combination of
these drugs. At 42 h posttransfection, cells were lysed and assayed for luciferase
activity (Promega). Luciferase activities derived from the HIV-1 LTRs were
normalized with respect to protein concentration using the detergent-compatible
protein assay (Bio-Rad).
EMSAs. Nuclear extracts were prepared, and electrophoretic mobility shift
assays (EMSAs) with the HIV-1 NF-B probe were performed as previously
described (54). For supershift assays, monoclonal antibody against p52 (catalog
no. 05-361; Upstate Biotechnology) and polyclonal antibodies against p50 (cat-
alog no. 06-886; Upstate Biotechnology), p65 (catalog no. sc-109X; Santa Cruz
Biotechnology, Inc.), RelB (catalog no. sc-226X; Santa Cruz Biotechnology,
Inc.), and c-rel (catalog no. sc-6955X; Santa Cruz Biotechnology, Inc.) were
added to the binding reaction at a final concentration of 2 g/reaction mixture.
As loading controls, the same nuclear extracts were tested for binding of Oct-1
to an Oct-1 consensus probe (5-TGTCGAATGCAAATCACTAGAA-3).
RNase protection assays. Total RNA samples were prepared from SupT1 cells
or U1 cells using the commercial RNAqueous phenol-free total RNA isolation
kit (Ambion) from 5  106 cells treated or mock treated with TSA or NaBut
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or/and TNF during different periods of time. The HIV-1-specific antisense ribo-
probe was obtained as previously described (54). An IB-specific 32P-labeled
antisense riboprobe was synthesized in vitro by transcription of AflIII-restricted
pcDNA3-IB with SP6 polymerase according to the protocol provided with the
riboprobe in vitro transcription systems (Promega). As control, a glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)-specific antisense probe was synthesized
by the same method and used on the same RNA samples.
The RNase protection assays were performed with the RPA II kit (Ambion)
according to the manufacturer’s recommendations. Briefly, hybridization reac-
tion mixtures (20 l) containing 12 g of total cellular RNA and 200,000 cpm of
probe in hybridization buffer were heated to 95°C for 4 min to denature the RNA
and then incubated at 42°C for 16 h. The reaction mixtures were diluted by the
addition of 200 l of digestion buffer, and the single-stranded sequences were
digested with RNase T1 and RNase A for 1 h at 37°C. Following addition of 300
l of inactivation buffer and ethanol precipitation, the protected RNA fragments
were analyzed by electrophoresis through 6% urea polyacrylamide gels.
Western blot analysis. Nuclear and cytoplasmic extracts were prepared as
previously described (in references 37 and 47, respectively). Western blots were
realized (47) with antibodies against the following proteins (each at a 1:1,000
dilution): IB (catalog no. 06-494; Upstate Biotechnology), IB (catalog no.
sc-945; Santa Cruz Biotechnology, Inc.), IBε (catalog no. sc-7156; Santa Cruz
Biotechnology, Inc.), and p65 (catalog no. sc-109X; Santa Cruz Biotechnology,
Inc.).
HIV-1 infections and CA-p24 measurements. HIV-1 infectious DNA was
prepared from the pHIV (57). Infectious viral stocks and infections were per-
formed as previously described (57). One day after infection, the cells were
treated or mock treated with TSA or/and TNF. Every 2 days, aliquots of 200 l
were removed from the infected cultures and replaced by complete RPMI 1640
medium. The aliquots were assayed for CA-p24 antigen concentration by an
enzyme-linked immunosorbent assay (Innogenetics) in order to monitor the
kinetics of viral replication.
Immunofluorescence confocal microscopy. SupT1 cells were treated or not
with TSA (450 nM) and/or TNF (50 ng/ml). After a 30-min or 2-h treatment, cells
were centrifuged (with cytospin 3; Shandon) and fixed for 5 min with Immuno-
histofix (Bio-Rad) at room temperature followed by 6 min with 100% methanol
at 20°C. After two washes with phosphate-buffered saline (PBS), the samples
were saturated with PBS containing 0.5% gelatin and 0.25% bovine serum
albumin for 1 h and stained for 1 h with a 1/100 dilution of an anti-human p65
rabbit polyclonal immunoglobulin G (IgG) (C-20; catalog no. sc-372; Santa Cruz
Biotechnology, Inc.). The samples were then washed three times with PBS
containing 0.2% gelatin and incubated for 1 h with a 1/200 dilution of the
secondary antibody: Alexa-488-coupled goat anti-rabbit IgG (Molecular Probes).
The samples were then washed three times in PBS with 0.2% gelatin and
mounted for analysis on a Zeiss LSM510 laser scanning confocal microscope.
RESULTS
TSA inducibility of different deleted HIV-1 LTRs. In order
to delineate the LTR sequences responsible for activation of
the HIV-1 promoter activity in response to TSA, we generated
a series of pLTR-luciferase reporter constructs containing var-
ious 5 and/or 3 deletions within the viral promoter region
(the prototype LAI strain of HIV-1 subtype B). The five re-
sulting plasmids were designated pLTR(1-789)-luc (containing
the complete 5 LTR plus the leader region up to the begin-
ning of the GAG open reading frame), pLTR(292-789)-luc,
pLTR(1-531)-luc, pLTR(292-531)-luc, and pLTR(345-531)-
luc, respectively (Fig. 1A). These plasmids were transiently
transfected into the human CD4 T-lymphoid cell line SupT1.
Transfected cells were mock treated or treated with increasing
concentrations of TSA (0, 250, 500, and 1,000 nM) and assayed
for luciferase activity. Results presented in Fig. 1B show the
TSA inductions for each construct to eliminate the variations
due to the differences in basal activity observed with the vari-
ous deleted LTRs. All LTR constructs were activated by TSA
in a dose-dependent manner. pLTR(1-789)-luc and pLTR
(292-789)-luc were induced 13.8- to 27.0-fold and 10.9- to 27.6-
fold, respectively. This induction by TSA is likely to be ex-
plained by histone hyperacetylation (48, 49, 54, 55) and/or by
acetylation and deacetylation phenomena involved in the reg-
ulation of transcription factors binding to the LTR.
The constructs pLTR(1-531)-luc, pLTR(292-531)-luc, and
pLTR(345-531)-luc presented TSA activations from 3.51- to
17.2-fold, from 4.57- to 11.2-fold, and from 5.14- to 11.6-fold,
respectively (Fig. 1B), indicating a decrease in TSA inducibility
associated with the deletion of the 3 region encompassing
nucleotides (nt) 532 to 789. A possible explanation for this
decrease in TSA inducibility would be the absence of the nu-
cleosome nuc-1 in the LTR constructs with 3 deletions when
assembled into chromatin, since an important part of the DNA
sequence wrapped around nuc-1 was lacking in these con-
structs (Fig. 1A).
Importantly, a significant TSA inducibility was still observed
with the smallest LTR (nt 345 to 531), containing the two B
sites, the three Sp1 sites, the TATA box and the ligand binding
protein 1 (LBP-1)/YY1 site (Fig. 1A and B). This could be
explained by the recruitment at the level of these sites of
different factors implicated in acetylation and deacetylation
events: TATA-binding protein (TBP)-associated factor II250
(34), transcription factor IIE (TFIIE) and TFIIF (21), Sp1
(10, 50), YY1 (9), and p65 (17, 40).
Synergistic activation of HIV-1 promoter activity by NF-B
and TSA. The HIV-1 NF-B binding sites confer a high rate of
transcription to the viral promoter in activated T cells and
monocytes/macrophages (reviewed in reference 44). In order
to investigate the functional role of NF-B in the inducibility of
the LTR by TSA, SupT1 cells were transiently cotransfected
with the pLTR(345-531)-luc construct and with increasing
amounts (from 6 ng each to 1,600 ng each) of expression
vectors for p50 and p65 (pRSV-p50/pRSV-p65). Cells were
treated with TSA or mock treated and assayed for luciferase
activity (Table 1). As expected, in the absence of TSA, p50/p65
trans-activated the HIV-1 promoter in a dose-dependent man-
ner up to 7.66-fold (Table 1, p50/p65-fold activation, rows 2 to
13). Treatment of cells with TSA alone resulted in a 51.8-fold
activation of transcription (Table 1, row 1). Remarkably, when
cells were both cotransfected with increasing amounts of ex-
pression vectors for p50/p65 and treated with TSA, a strong
synergism was observed between the two activators, resulting
in transactivations ranging from 95.0- to 2,655-fold (Table 1,
p50/p65 plus TSA activation, rows 2 to 13). Transcriptional
activators synergize when their combination produces a tran-
scriptional rate that is greater than the sum of the effects
produced by the individual activators. Transfection of 1,200 ng
each of pRSV-p50/pRSV-p65 led to a 7.38-fold stimulation of
transcription in the absence of TSA, whereas in presence of
TSA, it led to a 2,655-fold stimulation (Table 1, row 11). This
amount of transcription is 45-fold greater (45-fold synergism)
than the sum of the effects produced by each activator sepa-
rately (51.8-fold  7.38-fold) (Table 1, rows 1 and 11). This
synergism between p50/p65 and TSA persisted even at satu-
rating amounts of p50/p65 proteins (see data for 1,400 and
1,600 ng each of cotransfected p50/p65 plasmid DNAs), indi-
cating that the observed effect was not the consequence of
increased p50/p65 expression due to activation of the RSV
promoter by TSA.
Synergistic activation by ectopically expressed p50/p65 and
TSA required intact NF-B binding sites in the HIV-1 proxi-
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mal enhancer, since point mutations in these sites eliminated
this effect [Table 1, pLTR(345-531)mut B-luc, rows 14 to 26].
This implies that the synergistic effect was mediated by inter-
actions at the B sites and not at the otherwise intact
LTR(345-531) DNA sequences.
In conclusion, these results demonstrate that TSA synergis-
tically enhanced NF-B-dependent transcriptional activation
of the HIV-1 promoter, suggesting that the NF-B signaling
pathway can be functionally regulated by posttranslational
acetylation in vivo.
Synergistic activation of HIV-1 promoter activity by cyto-
kine TNF and deacetylase inhibitors. Proinflammatory cyto-
kine TNF stimulates the HIV-1 LTR through activation of
NF-B in both human CD4 T cells and monocytes/macro-
phages. To determine whether the synergism between NF-B
and deacetylase inhibitor TSA could be observed in the context
of a physiological activation of the NF-B pathway, we exam-
ined the effect of deacetylase inhibitors, TSA and NaBut, on
the TNF-induced HIV-1 promoter activity. To this end, SupT1
cells were transiently transfected with the reporter construct
pLTR(345-531)-luc or pLTR(345-531)mut B-luc and subse-
quently mock treated or treated with TNF alone, TSA alone,
NaBut alone, TNF-TSA, or TNF-NaBut. Treatment of SupT1
cells with TSA, NaBut, or TNF alone resulted in a 43.5-, 27.2-,
or 7.61-fold increase, respectively, of luciferase gene expres-
sion driven by the wild-type LTR (Fig. 2). Remarkably, when
cells were treated with a combination of TNF-TSA or TNF-
NaBut, we observed a 287- or 261-fold increase of luciferase
expression above the control level obtained in absence of any
treatment, demonstrating an important synergism between
TNF and deacetylase inhibitors. Mutation in the B sites
[pLTR(345-531)mut B-luc] eliminated both the activation of
the LTR by TNF and its synergistic activation by TSA (NaBut)
and TNF (Fig. 2). Moreover, results obtained by transient
transfection of the promonocytic cell line HL60 confirmed
those observed with the CD4-T-lymphoid-cell line SupT1
(data not shown). Thus, the synergism between TNF and TSA
(NaBut) was thus observed in two cell lines representative of
the two major cellular targets for HIV-1 infection.
In conclusion, our functional results demonstrate that the
FIG. 1. TSA responsiveness of different HIV-1 LTRs with deletions. (A) Organization of the 5 LTR region of the prototype HIV-1 virus LAI
(subtype B). The LTR is composed of the U3, R, and U5 regions. The complete LTR and the leader region (nt 1 to 789) (nt 1 is the start of
U3 in the 5 LTR) control the luciferase reporter gene. The transcription factor binding sites present in the different LTRs with deletions are
detailed for each construct and are aligned with nucleosome positioning (grey ovals). The following transcription factor binding sites are present
in the full-length LTR construct (reviewed in reference 38): two AP1/COUP sites, the nuclear receptor-responsive element (NRRE), one c-Myb
site, three NF-AT sites, one GR site, one USF site, one Ets-1 site, one TCF/LEF site, two B sites, five Sp1 sites, the TATA box, one LBP-1/YY1
site, three AP-1 sites, and one IRF site. (B) SupT1 cells were transiently transfected with 500 ng of each reporter construct containing the different
HIV-1 LTRs with deletions, and cells were treated with increasing concentrations of TSA. Luciferase activities were measured in cell lysates. To
compare the TSA responsiveness of the different LTRs, basal LTR activity of each construct was arbitrarily set at a value of 1. Results are presented
as histograms indicating the TSA inductions of the constructs with respect to their respective basal activity. Values represent the means of duplicate
samples. An experiment representative of three independent transfections is shown. Variation for a given plasmid between different experiments
was 	15% in most cases.
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deacetylase inhibitors TSA and NaBut functionally synergized
with TNF to activate the HIV-1 LTR. The synergism we ob-
served between TSA (NaBut) and TNF was strictly dependent
on the presence of intact B sites in the HIV-1 proximal
enhancer.
Synergistic activation by TSA and TNF of LTR activity from
the HIV-1 subtypes A through G of group M. HIV-1 isolates
have been classified into three genetic groups: the major group
(M), the outlier group (O), and the non-M, non-O group (N).
All groups are thought to have arisen from independent zoo-
notic transmissions. The group M isolates, which are respon-
sible for more than 99% of all infections, have diversified
during their worldwide spread. These isolates have been
grouped according to their genomic sequences and can be
divided into 10 distinct subtypes termed A through J. Although
there is some variation in the exact position and in the se-
quence of B sites, two similar sites are present in the LTRs of
most described HIV-1 isolates, including isolates from sub-
types A and B (used in the above experiments and most ex-
tensively studied in laboratories) and subtypes D, F, G, and
AG (the last of which is a recombinant between subtypes A
and G). On the other hand, subtype C viruses generally contain
three B sites, whereas subtype E viruses contain one func-
tional B site (23).
To examine the impact on the TNF-TSA synergism of these
differences among the various HIV-1 group M subtypes, we
performed transient transfections of SupT1 cells with reporter
luciferase constructs containing LTRs from subtypes A, B, C1,
D, E, F, G, and AG. Transfected LTRs were assayed for their
responsiveness to TSA, to TNF and to both agents in combi-
nation. Results presented in Fig. 3 show the induction for each
subtype (obtained by dividing the induced luciferase activities
of subtype X by the basal activity of this same subtype X) in
order to eliminate subtype-specific differences in basal activity
of the LTRs.
LTR activity of each subtype tested was induced by TNF
alone from 2.55- to 6.63-fold and by TSA alone from 26.2- to
63.6-fold depending on the subtype (Fig. 3). Importantly, TNF-
TSA together synergized to activate all the subtype LTRs.
Subtype E, containing one B site, was induced 169-fold by
TNF-TSA, corresponding to a 3.7-fold synergism. The sub-
types A, B, D, F, G, and AG, each containing two B sites,
presented inductions from 216- to 596-fold, corresponding to
synergisms from 5.1- to 11-fold. Subtype C1, containing three
TABLE 1. Synergistic activation of HIV-1 promoter by NF-B (p50/p65) and TSAa




assay (RLU) Activation (fold) with: Synergism
(fold)
TSA TSA p50/p65 p50/p65  TSA
1 pLTR(345-531)-luc 2.58 133 1.00 51.8
2 6 2.99 245 1.16 95.0 1.8
3 25 2.43 530 1.94 205 3.9
4 50 2.92 811 1.13 314 6.0
5 100 8.01 2,961 3.11 1,148 21
6 200 6.15 2,723 2.39 1,055 20
7 400 11.8 2,631 4.59 1,020 18
8 600 11.5 4,102 4.45 1,590 28
9 800 10.9 6,129 4.24 2,376 43
10 1,000 14.1 5,809 5.46 2,252 39
11 1,200 19.0 6,851 7.38 2,655 45
12 1,400 19.7 5,394 7.66 2,091 35
13 1,600 18.3 3,189 7.10 1,236 21
14 pLTR(345-531)mut B-luc 1.55 101 1.00 65.0
15 6 2.02 115 1.31 74.2 1.1
16 25 1.87 90.0 1.21 58.1 0.9
17 50 2.05 130 1.32 84.1 1.3
18 100 3.30 161 2.13 104 1.6
19 200 1.80 82.5 1.16 53.2 0.8
20 400 2.10 98.8 1.36 63.7 1.0
21 600 1.88 70.2 1.21 45.3 0.7
22 800 1.55 71.6 1.00 46.2 0.7
23 1,000 1.79 95.7 1.16 61.8 0.9
24 1,200 1.51 97.8 0.98 61.2 0.9
25 1,400 1.76 129 1.14 83.2 1.3
26 1,600 0.97 66.0 0.63 42.6 0.7
a SupT1 cells were transiently cotransfected with 500 ng of either pLTR(345–531)-luc (rows 1 to 13) or pLTR(345–531)mut B-luc (rows 14 to 26) and increasing
amounts of expression vectors for p50 and p65 (from 6 to 1,600 ng of each vector). Cells were mock treated (TSA) or treated with TSA (TSA). Luciferase assay
results are represented as relative light units (RLU). For rows 1 to 13, p50/p65 activations were obtained by dividing the RLUs in the TSA column for
pLTR(345-531)-luc by the RLU result obtained for this construct in the absence of both TSA and p50/p65. The p50/p65  TSA activations were obtained by dividing
the RLUs in the TSA column for pLTR(345-531)-luc by the RLU result obtained for this construct in the absence of both TSA and p50/p65. Similarly, for rows 14
to 26, p50/p65 activations were obtained by dividing the RLUs in the TSA column for pLTR(345-531)mut B-luc by the RLU result obtained for this construct in
the absence of both TSA and p50/p65. The p50/p65  TSA activations were obtained by dividing the RLUs in the TSA column for pLTR(345-531)mut B-luc by
the RLU result obtained for this construct in the absence of both TSA and p50/p65. The synergism was determined as previously described (19) using the following
formula: (fold activation by TSA  p50/p65)/(fold activation by TSA alone  fold activation by p50/p65 alone). An experiment representative of five repeated
transfections is shown.
b Same amount for each.
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B sites, was activated 802-fold by TNF-TSA, corresponding to
a 11.8-fold synergism, a synergism three times higher than that
observed for subtype E (Fig. 3).
From these experiments, we conclude that the synergistic
transcriptional activation of the LTR by TNF-TSA is a com-
mon feature of HIV-1 subtypes A through G. In addition, we
measured a positive correlation between the number of B
sites present in the respective LTRs and the amplitude of the
synergism between TNF and TSA.
Synergistic activation by TNF and TSA of HIV-1 replication
following infection of U937 cells. To assess the biological rel-
evance of the TNF-TSA synergism, we tested the effects of
these drugs on viral replication in the context of an infection by
HIV-1. To this end, we infected U937 monocytic cells with an
HIV-1 NL4-3 stock. One day after infection, cells were mock
treated or treated with either TSA, TNF, or both activators.
HIV-1 replication was monitored by measuring the concentra-
tion of CA-p24 gag antigen in the culture supernatants over a
15-day period (Fig. 4). Our results indicated that, in absence of
any treatment, infection resulted in progressive virus produc-
tion. Following treatment with TSA alone or TNF alone,
HIV-1 NL4-3 replicated more efficiently with levels of virus
production higher than the control level. Importantly, TNF-
TSA together synergized to enhance virus production at each
time point. At day 15, TSA alone, TNF alone, and TNF-TSA
increased CA-p24 levels by two-, three-, and eightfold, respec-
tively, above the control level obtained in the absence of any
treatment.
Our data indicate that TNF and TSA synergistically in-
creased the replicative capacity of the HIV-1 NL4-3 virus in
U937 cells. These results were confirmed in three independent
infection experiments performed in triplicate and were consis-
tent with the results of the LTR-luciferase assays.
Thus, while the transcriptional activation of the HIV-1 pro-
moter in response to TSA had been previously demonstrated
in ex vivo transiently or stably transfected HIV LTR reporter
constructs (26, 30), in latently HIV-infected cell lines (54), and
on in vitro chromatin-reconstituted HIV-1 templates (48, 49),
the results presented here constitute the first demonstration of
the activating effect of a deacetylase inhibitor in the context of
a natural HIV-1 infection. Importantly, we demonstrated a
synergistic effect of TNF and TSA on the level of HIV-1 rep-
lication from a monocytic cell line, a cell lineage substantially
contributing to simian immunodeficiency virus latent reser-
voirs in monkeys (20).
Synergistic activation of HIV-1 transcription and replica-
tion by TNF and inhibitors of deacetylases in latently infected
cells. Different culture systems have served as in vitro models
for postintegration latency, and the study of these cells has
provided important insight into the mechanism of transcrip-
tional reactivation and pathogenesis of HIV. The U1 mono-
cytic cell line (cloned from a population of chronically HIV-
1-infected U937 cells) is one of the most-studied models of
postintegration latency. The inducing effect of TNF on endog-
enous HIV-1 replication in U1 cells has been correlated with
the activation of NF-B binding to the viral enhancer and the
stimulation of newly transcribed HIV-1 RNAs (43).
FIG. 2. Synergistic activation of HIV-1 promoter by cytokine TNF
and inhibitors of deacetylases, TSA, and NaBut. SupT1 cells were
transiently transfected with 500 ng of the indicated constructs. Cells
were mock treated or treated with TSA, NaBut, TNF, TNF-TSA, or
TNF-NaBut. The mock-treated value of the wild-type LTR reporter
construct was arbitrarily set at a value of 1. Values represent the means
of duplicate samples. A representative experiment of three indepen-
dent transfections is shown. Variation for a given plasmid between
different experiments was 	15% in most cases.
FIG. 3. Synergistic activation by TSA and TNF of the LTRs from
the HIV-1 group M subtypes A through G. SupT1 cells were tran-
siently transfected with 500 ng of an LTR luciferase construct contain-
ing the fragment from nt147 to63 of the subtype LTRs (A through
G and AG as indicated). Results are presented as histograms indicat-
ing inductions by TSA, TNF, or TNF-TSA with respect to the basal
activity of each subtype LTR construct, which was assigned a value of
1. Values represent the means of duplicate samples. An experiment
representative of three independent transfections is shown. Variation
for a given plasmid between different experiments was 	15% in most
cases.
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To study the effect of deacetylase inhibitors on HIV reacti-
vation, we treated the latently infected cell line U1 for 24 h
with TSA, TNF, NaBut, TNF-TSA, or TNF-NaBut. Treatment
with TSA alone, TNF alone, or NaBut alone resulted in in-
creases in p24 antigen release of 47.3-, 30.3-, and 118-fold,
respectively, confirming the previous observations from our
laboratory (54) (Fig. 5A). Induction by TNF-TSA and TNF-
NaBut caused a 674- and 650-fold activation of virus produc-
tion, respectively (Fig. 5A). This synergistic activation by TSA
(NaBut) and TNF of virus production in U1 cells took place at
the transcriptional level. Indeed, RNase protection analysis
with an antisense riboprobe corresponding to the HIV LTR
showed that treatment with TSA or NaBut resulted in a 4.3- or
6.3-fold increase of HIV-1 transcription, to a degree similar to
that observed following TNF treatment (Fig. 5B and C). After
treatment with TNF-TSA and TNF-NaBut, we observed a 42-
and 48-fold induction of the steady-state HIV mRNA level,
respectively, above the mRNA level measured in the absence
of any treatment. Our data thus demonstrated a synergistic
activation by TNF and deacetylase inhibitors of HIV-1 tran-
scription in latently infected U1 cells. As an internal control,
RNase protection analysis of the same RNA samples using an
antisense riboprobe corresponding to the housekeeping gene
for GAPDH showed no change in the level of mRNA follow-
ing treatment with any drug alone or in combination (Fig. 5B).
These results demonstrate that the combination of TNF with
a deacetylase inhibitor has a synergistic effect on reactivation
of HIV-1 transcription and replication in the latently infected
U1 cell line.
Deacetylase inhibitors TSA and NaBut prolong TNF-in-
duced NF-B binding to DNA. To examine the effect of
deacetylase inhibitors on NF-B binding to DNA, EMSAs
were performed by using as a probe an oligonucleotide corre-
sponding to the two B sites from the prototype virus LAI of
subtype B (54). This probe was incubated with nuclear extracts
prepared from SupT1 cells either mock treated or treated with
TSA, TNF, NaBut, TNF-TSA, or TNF-NaBut for different
periods of time (30 min, 1 h, 2 h, and 4 h) (Fig. 6A). As
expected, a rapid appearance of NF-B binding activity was
observed in response to TNF (Fig. 6A, lane 3). We showed by
supershift assays using antibodies directed against individual
members of the NF-B family that these two retarded com-
plexes corresponded to p50/p65 heterodimers and to p65/p65
homodimers, respectively (Fig. 6B). NF-B appeared after a
30-min treatment and faded away after a 1-h treatment (Fig.
6A, lane 9). Treatment of cells with TSA alone or NaBut alone
caused no induction of NF-B binding activity even after a 4-h
treatment (Fig. 6A, lanes 2, 8, 14, and 20 or lanes 4, 10, 16, and
22, respectively). A 30-min treatment with TNF-TSA or TNF-
NaBut caused an induction of NF-B binding activity identical
to that obtained with TNF alone (Fig. 6A, lanes 5 or 6).
Remarkably, when we compared induction by TNF alone with
the inductions by TNF-TSA or TNF-NaBut at later times (1, 2,
and 4 h), we observed that NF-B binding activity was pro-
longed up to 4 h in the presence of TNF-TSA or TNF-NaBut
(Fig. 6A, compare lane 9 with lanes 11 and 12, lane 15 with
lanes 17 and 18, and lane 21 with lanes 23 and 24). This finding
indicated a sustained NF-B binding to DNA after TNF-TSA
or TNF-NaBut versus TNF treatment. TSA (NaBut) did not
alter the binding of the constitutively expressed Oct-1 tran-
scription factor in either the presence or absence of TNF (Fig.
6A, lower panel).
Taken together, these in vitro binding studies demonstrate
that deacetylase inhibitors TSA and NaBut prolonged TNF-
induced NF-B binding to DNA but did not themselves stim-
ulate NF-B binding.
The presence of p65 is sustained in the nuclei of TNF-
stimulated SupT1 cells in response to TSA or NaBut. The
same nuclear extracts used in EMSAs were also examined by
Western blotting with an anti-p65 antibody in order to monitor
the presence of p65 as a function of time in the nucleus after
treatment with TSA, TNF, NaBut, TNF-TSA, or TNF-NaBut.
Immunoblotting revealed sustained nuclear p65 presence after
TNF-TSA (NaBut) versus TNF treatment (Fig. 6C).
To study the effect of deacetylase inhibitors on the subcel-
lular distribution of p65, we monitored by confocal microscopy
the localization of the endogenous p65 protein during stimu-
lation with TSA, TNF, or both in combination (Fig. 6D). In
unstimulated SupT1 cells, p65 was localized predominantly in
the cytoplasmic compartment (Fig. 6D, panel a). Treatment
with TSA for 30 min or 2 h did not alter this subcellular
distribution (Fig. 6D, panel b or e, respectively). Treatment
with TNF led after 30 min to the migration of p65 to the
nucleus (Fig. 6D, panel c). This was transient, since, following
FIG. 4. Synergistic effect of TSA and TNF on HIV-1 replication in
monocytic cells. U937 cells were infected with an HIV-1 NL4-3 infec-
tious stock. One day after infection, cells were mock treated or treated
with TSA, TNF, or TNF-TSA. Virus replication was monitored at
different intervals (every 2 days) by measuring the CA-p24 concentra-
tion in the culture supernatants. For each time point, CA-p24 was
quantified from independent triplicate infections and the means of the
triplicate samples are presented. An experiment representative of four
independent infections performed in triplicate is shown.
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2 h of treatment with TNF, we observed the return of the
nuclear p65 to the cytoplasm (Fig. 6D, panel f). A 30-min
treatment with TNF-TSA caused a translocation of p65 into
the nucleus identical to that observed with TNF alone (Fig. 6D,
compare panels c and d). In contrast, comparison between
both treatments at the 2 h-time point indicated that TSA treat-
ment prolonged the TNF-induced nuclear translocation of p65
(Fig. 6D, compare panels f and g).
These results indicate that the prolonged NF-B binding to
DNA we observed after TNF-TSA (NaBut) versus TNF treat-
ment (Fig. 6A) coincided with a prolonged intranuclear pres-
ence of p65.
Delay in the cytoplasmic recovery of IB in response to
TNF-TSA versus TNF treatment. The nuclear expression and
action of NF-B require signal-coupled phosphorylation and
degradation of the IB inhibitory proteins, which normally
bind and sequester NF-B in the cytoplasm. The activation of
de novo IB gene expression by NF-B likely plays a key role
in the termination of nuclear NF-B action, thereby ensuring a
transient NF-B transcriptional response. Therefore, we rea-
soned that the prolonged nuclear binding activity and presence
of NF-B we observed in response to TNF-TSA versus TNF
treatment could result from a delay in cytoplasmic IB re-
covery.
To test this hypothesis, we monitored the presence of the
IBs as a function of time in the cytoplasm after treatment with
TSA, TNF, or TNF-TSA. Cytoplasmic extracts were prepared
from SupT1 cells treated with these activators for different
periods of time (30 min, 1 h, 2 h, and 4 h) and analyzed for
IB, IB, and IBε expression by Western blotting. TSA
alone did not induce IB degradation (Fig. 7A, lanes 2, 6, 10,
and 14). As expected, TNF induced a rapid degradation of the
IB protein (Fig. 7A, lane 3) followed by its recovery, which
was completed 1 h after stimulation (Fig. 7A, lane 7). After
TNF-TSA treatment, rapid IB degradation was also ob-
served (Fig. 7A, lane 4), but in contrast to what we saw with
TNF alone, its recovery was delayed up to more than 2 h (Fig.
7A, compare lane 7 with lane 8 and lane 11 with lane 12). No
change in IB and IBε cytoplasmic concentration was ob-
served after any treatment. Similar results were obtained when
examining the combined effect of TNF and NaBut (data not
shown). Moreover, we confirmed the delay in cytoplasmic
IB recovery in response to TNF-TSA versus TNF treatment
using cytoplasmic extracts prepared from U1 cells (data not
shown).
We analyzed the steady-state level of IB mRNA by
RNase protection assay using an IB-specific antisense ribo-
probe and RNA samples prepared from SupT1 cells treated or
not for 2 h with either TNF or TNF-TSA (Fig. 7B). We ob-
served similar strong activations of IB transcription follow-
ing TNF or TNF-TSA treatment (Fig. 7B), thereby indicating
that TSA did not prevent the TNF-dependent transcriptional
activation of IB. Control RNase protection analysis of the
FIG. 5. Synergistic activation of HIV-1 transcription and virus pro-
duction by deacetylase inhibitors and TNF in the latently infected cell
line U1. (A) U1 cells were mock treated or treated with TSA, TNF,
NaBut, TNF-TSA, or TNF-NaBut. At 24 h posttreatment, viral pro-
duction was estimated by measuring CA-p24 antigen concentration in
supernatants. The mock-treated value was arbitrarily set at a value of
1. Each point is the average of triplicate cultures performed in the
same experiment. The error bars show the standard errors of the mean.
A representative experiment out of four independent experiments is
shown. (B) RNase protection analysis after a 6 h-treatment of U1 cells
with the same activators as in panel A. To detect HIV-1 RNA, total
RNA samples were incubated with an antisense riboprobe correspond-
ing to the HIV-1 LTRs. The figure shows the 3 LTR protected band
(bottom panel). As a control, the same RNA samples were incubated
with a specific probe corresponding to the GAPDH gene (top panel).
(C) Relative levels of HIV mRNA shown in panel B (bottom) were
quantified by radioimaging analysis using an Instant Imager (Packard).
The HIV mRNA level in untreated U1 cells was assigned a value of 1.
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same RNA samples using a GAPDH riboprobe showed no
difference in the mRNA levels (Fig. 7B).
Our results thus demonstrate a marked delay in the cyto-
plasmic recovery of the NF-B inhibitor, IB, after TNF-TSA
versus TNF treatment. This delay was not due to a defect in the
steady-state level of IB mRNA and coincided with the sus-
tained NF-B binding activity and the sustained intranuclear
presence of p65 that we observed after TNF-TSA versus TNF
treatment by EMSAs, immunoblotting, and confocal micros-
copy. This delay could explain the strong transcriptional syn-
ergism we observed between NF-B and TSA on the HIV-1
promoter.
The TNF-TSA synergistic activation of HIV-1 transcription
coincides with the prolonged nuclear level of NF-B. To de-
termine whether a temporal correlation existed between the
synergistic transcriptional activation of the HIV-1 promoter
and the prolonged nuclear level of NF-B, we examined by
RNase protection the time course of HIV transcription in
FIG. 6. Sustained NF-B binding to DNA after TNF-TSA (NaBut) versus TNF treatment. (A) EMSA analysis of NF-B binding activity.
Nuclear extracts were prepared from SupT1 cells mock treated or treated with TSA, TNF, NaBut, TNF-TSA, or TNF-NaBut for different periods
of time. An oligonucleotide corresponding to the LTR B sites was used as probe. As a control for equal loading, the lower panel shows
comparability of the various nuclear extracts assessed by EMSA with an Oct-1 consensus probe. (B) Supershift assays. The HIV-1 B site
oligonucleotide probe was incubated with 5 g of nuclear extracts from SupT1 cells treated for 2 h with TNF-TSA. Next, antibodies directed against
different members of the NF-B family (lanes 2 to 6) or purified rabbit IgG as a negative control (lane 1) were added to the binding reaction.
(C) Western blot analysis of levels of the p65 protein in SupT1 cells mock treated or treated with TNF and/or TSA (NaBut). The same nuclear
extracts used in panel A were fractionated by electrophoresis, and the Western blots were probed with an anti-p65-specific antibody. (D) Immu-
nofluorescence analysis of the p65 protein in SupT1 cells mock treated or treated with TNF and/or TSA. Subcellular localization of endogenous
p65 was assessed by indirect immunofluorescence with a rabbit polyclonal anti-p65 IgG antibody and a goat anti-rabbit IgG antibody coupled with
Alexa-488 (green color). SupT1 cells were left unstimulated or were stimulated with TNF and/or TSA for the indicated periods of time.
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response to TNF and/or TSA. Total RNA samples were pre-
pared from latently infected U1 cells treated or not with TSA,
TNF, or TNF-TSA for different periods of time (30 min, 1 h,
2 h, and 4 h) (Fig. 8). The steady-state level of HIV-1 mRNA
was evaluated using an HIV-1 promoter-specific probe. Treat-
ment with TSA alone caused 1.3-, 2.1-, 2.6-, and 6.5-fold in-
ductions of HIV-1 transcription after 30-min, 1-h, 2-h, and 4-h
treatments, respectively (Fig. 8A [bottom panel] and B). Treat-
ment with TNF alone caused 3.7-, 3.1-, 6.9-, and 7.9-fold HIV-1
mRNA inductions after 30 min-, 1 h-, 2 h- and 4 h-treatments,
respectively (Fig. 8A [bottom panel] and B). Treatment with
TNF-TSA caused 4.4-, 9.3-, 22-, and 47-fold inductions of LTR
transcriptional activity after 30-min, 1-h, 2-h, and 4-h treat-
ments, respectively (Fig. 8A [bottom panel] and B). GAPDH
mRNA levels were unaffected by treatment with any drug
alone or in combination (Fig. 8A). Therefore, the TNF-TSA
synergistic effect at the mRNA level was detectable 1 h after
addition of drugs to the cells and gradually increased over
time. Our results thus demonstrate that the TNF-TSA syner-
gistic activation of HIV-1 transcription was temporally parallel
to the prolonged presence and binding of NF-B in the nucleus
(observed in Fig. 6).
DISCUSSION
In summary, our results demonstrate a synergistic activation
of the HIV-1 transcriptional promoter activity by NF-B and
inhibitors of deacetylases in transient transfection reporter as-
says and in acutely and latently infected cell lines. We provide
a molecular explanation for this synergism by demonstrating a
marked delay in the cytoplasmic recovery of IB in response
to TNF-TSA (NaBut) versus TNF treatment and a temporal
correlation between this delayed recovery and a prolonged
binding activity and presence of NF-B in the nucleus.
In this study, we have shown by deletion analysis that the
TSA inducibility of the HIV-1 promoter required diverse se-
quences scattered throughout the LTR. The TSA response of
the HIV LTR is likely to be explained by histone hyperacety-
FIG. 7. (A) Delay in cytoplasmic IB recovery in response to
TNF-TSA versus TNF treatment. Cytoplasmic extracts were prepared
from SupT1 cells untreated or treated with TNF and/or TSA for
various times, and Western blot analyses of levels of the IB, IB
and IBε were performed with specific antibodies against these pro-
teins. (B) TSA did not prevent the TNF-dependent transcriptional
activation of IB. RNase protection analysis after a 2 h-treatment of
SupT1 cells with TNF or TNF-TSA. To detect IB RNA, total RNA
samples were incubated with an antisense riboprobe corresponding to
the IB gene (top panel). The figure shows the 162-nt IB protected
band. As a control, the same RNA samples were incubated with a
specific probe corresponding to the GAPDH gene (bottom panel).
FIG. 8. Time course of HIV-1 transcriptional activation in re-
sponse to TNF and/or TSA. (A) RNase protection analysis after 30-
min, 1-h, 2-h, and 4-h treatments of U1 cells with TSA, TNF, or
TNF-TSA. To detect HIV-1 RNA, total RNA samples were incubated
with an antisense riboprobe corresponding to the HIV-1 LTRs. The
figure shows the 3 LTR protected band (bottom panel). As a control,
the same RNA samples were incubated with a specific probe corre-
sponding to the GAPDH gene (top panel). (B) Relative levels of HIV
mRNA shown in panel A (bottom) were quantified by radioimaging
analysis using an Instant Imager (Packard). The HIV mRNA level in
untreated U1 cells was assigned a value of 1.
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lation. Indeed, our laboratory has previously demonstrated by
chromatin mapping experiments that a nucleosome (nuc-1)
positioned immediately downstream of the transcription start
site is remodeled upon activation of the HIV promoter in
response to HDAC inhibitors (54). Nuc-1 is likely to be the
unique nucleosome target of action of the deacetylases since it
is the only nucleosome whose structure or conformation is
affected when deacetylases are inhibited (54). Although we did
not investigate in the present study the chromatin organization
of the transiently transfected LTR templates, we speculated
that our LTR templates with deletions exhibited nucleosome
positioning similar to that observed in vivo. Indeed, it is known
that transfected DNA rapidly assembles into minichromo-
somes with histones attached (45). Moreover, the DEAE-dex-
tran transfection technique we used here allows the typical
160-bp DNA ladder characteristic of the physiological nucleo-
somal DNA (24). Finally, in vitro chromatin-reconstituted
HIV-1 templates corroborate the native nucleosomal organi-
zation found in latently infected cells (48, 49).
Importantly, because of the numerous nonhistone protein
substrates for acetylation, the TSA response of the HIV-1
promoter could be explained in large part by acetylation and
deacetylation events involved in the regulation of nuclear fac-
tors binding to the LTR. On one hand, several of these factors,
including AP-1, ligand-bound nuclear hormone receptors, c-
Myb, glucocorticoid receptor (GR), NF-AT, E-box binding
proteins, Ets-1, TCF/LEF, NF-B, Sp1, interferon regulatory
factor (IRF), and the HIV trans-activator Tat have been shown
to interact with acetyltransferases. On the other hand, several
transcription factors that bind to the LTR, including unligan-
ded nuclear hormone receptors, GR, E-box binding proteins,
YY1, Sp1, TCF/LEF have been shown to interact with deacety-
lases. These factors therefore represent good candidates for
the specific targeting of acetyltransferases and deacetylases to
the HIV promoter, thereby regulating the acetylation level of
histones (in particular nuc-1 histones) and/or of transcription
factor substrates binding to the LTR (such as c-Myb, Sp1, IRF,
TFIIE and TFIIF, and Tat) (43a). The addition and removal
of acetyl groups on these histone and nonhistone proteins
could be crucial in controlling transcription initiation and elon-
gation.
Thus, the HIV promoter appears to contain numerous cis-
regulatory DNA elements involved in the inducibility of the
LTR by TSA. As such, the HIV promoter is representative of
a small subset (	2%) of cellular genes that have their expres-
sion upregulated by deacetylase inhibitors (55) and constitutes
a unique regulatory model system to study the complex rela-
tionship between acetylation processes and transcriptional ac-
tivity.
Importantly, a significant TSA inducibility was still observed
with a reduced LTR (nt 345 to 531), containing the two B
sites, the three Sp1 sites, the TATA box, and the LBP-1/YY1
site (Fig. 1A and B). This could be explained by the recruit-
ment at the level of these sites of different factors presenting
linkages with deacetylation and acetylation processes. (i) At
the Sp1 sites, Sp1 is acetylated in vitro by p300 and interacts
with p300, which acts as a coactivator for Sp1-mediated tran-
scriptional activation (50). Sp1 has also been shown to interact
directly with HDAC-1 (10). (ii) At the TATA box, the general
transcription factors TFIIE and TFIIF are acetylated in vitro
by P/CAF and p300 (21). The TFIID subunit TBP-associated
factor II250 is a histone acetyltransferase (34). (iii) At the
LBP-1 site, LBP functions as a docking molecule for YY1,
which in turn acts by recruiting HDAC-1. This ternary complex
represses the HIV-1 promoter, probably via the HDAC activity
since this repression is blocked by TSA (9). (iv) At the B
sites, NF-B-dependent gene expression requires the func-
tion of transcriptional coactivator proteins, including CBP/
p300, P/CAF, and SRC-1, which possess acetyltransferase
activity (17, 35, 40). Moreover, there is some evidence to
suggest that deacetylase inhibitors may function to positively
regulate NF-B transcriptional activity (53).
In the present study, we focused on the potential functional
role of these B sites in the TSA inducibility of the HIV-1 LTR
and demonstrated a strong transcriptional synergism between
deacetylase inhibitors and NF-B.
Mechanistically, we showed here by gel retardation assays
that TSA (or NaBut) prolonged TNF-induced NF-B DNA-
binding activity, whereas TSA (or NaBut) alone caused no
induction of NF-B. These in vitro binding studies coincided
with a sustained nuclear p65 presence as revealed by immuno-
blotting and confocal immunofluorescence microscopy. Impor-
tantly, Western blot analysis also revealed a marked delay in
the cytoplasmic reappearance of the inhibitory protein IB
after TNF-TSA versus TNF treatment. This delay correlated
temporally with the sustained binding activity and presence of
NF-B in the nucleus and was not due to a defect in the IB
mRNA production. These data therefore provide a molecular
mechanism involving IB for the functional synergism we
observed between TNF and inhibitors of deacetylases. IB
plays a pivotal role in the NF-B signaling pathway. Indeed,
the primary level of regulation of NF-B activity is through its
retention in the cytoplasm through interactions with IB.
Moreover, the resynthesis of de novo IB participates in a
negative feedback system ensuring a transient NF-B tran-
scriptional response (reviewed in reference 28). We are cur-
rently further investigating the role of TSA in the delayed
cytoplasmic reappearance of IB reported here. To this end,
we are testing whether some proteins involved in the NF-B/
IB signaling have their expression and/or action modulated by
TSA.
The molecular mechanisms mediating the TNF-TSA syner-
gism are likely to be highly complex and to implicate phenom-
ena other than the delayed cytoplasmic recovery of IB. On
one hand, the direct acetylation of Rel family members could
also intervene in the mechanism of synergistic activation by
TNF and TSA. In this regard, we have shown in a separate
study that the p65 and p50 NF-B subunits are weakly subject
to reversible acetylation (E. Adam, V. Quivy, and C. Van Lint,
unpublished results). In agreement, during the preparation of
the present work, W. Greene and colleagues reported that p65
is acetylated and that this posttranslational modification gov-
erns IB binding to p65 and the nuclear export of the NF-B
complex (4). On the other hand, deacetylase corepressor pro-
teins might be involved in the TNF-TSA synergism. Consistent
with this, we have recently shown by in vitro interaction assays
that HDAC-1, -3, and -4 can interact directly with the p65 and
p50 subunits of NF-B (Y. de Launoit and C. Van Lint, un-
published results). During the preparation of this manuscript,
two other groups have separately reported the interaction
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of p65 either with HDAC-1 (2) or with HDAC-3 (4). These
HDACs could repress expression of NF-B-regulated genes by
maintaining histones and/or other proteins in a deacetylated
state. TSA or NaBut, which inhibit the HDAC activity, would
increase NF-B-dependent transcription by alleviating the
chromatin- and/or factor-mediated block to transcriptional ac-
tivation.
The application of HAART has resulted in a major reduc-
tion of virus loads in individuals tolerating the regimen and
complying with its requirements, a stabilization of the clinical
course, and a significant decline in mortality. Nonetheless, the
persistence of HIV reservoirs has posed a sobering challenge
to the long-term control or eradication of HIV in infected
individuals receiving HAART (reviewed in reference 42).
These latently infected cells are a permanent source for reac-
tivation and lead to a rebound of viral load levels after inter-
ruption of HAART (15, 61). Activators of HIV expression
combined with HAART could lead to the elimination of the
latently infected cells and to the eradication of the infection.
Indeed, it is likely that the latently infected cells die upon
reactivation of virus (39) and that HAART prevents spread of
released virus to adjacent cells (5). In this report, we demon-
strate a synergistic effect of TNF and TSA (NaBut) for HIV-1
reactivation in the U1 cell line, a postintegration latency cell
culture model. It is important to note that an array of cyto-
kines, including the proinflammatory cytokines TNF and inter-
leukin-1 (inducers of NF-B), are already copiously expressed
in the microenvironment of the lymphoid tissues, which harbor
latent viral reservoirs (36). Therefore, our results suggest that
the use of deacetylases inhibitors in the treatment of HIV
infection may represent a valuable approach for purging the
latently infected reservoirs in HAART-treated individuals.
These deacetylase inhibitors would synergize with the TNF
already present at increased level in the serum of the HIV-
infected individuals. The possible clinical use of deacetylase
inhibitors raises several issues. First, these drugs do not act in
a cell-specific manner. Second, this class of agents is safely
administered for other diseases, including beta chain hemoglo-
binopathies (such as beta-thalassemia and sickle cell anemia)
(8, 11) and epilepsy and bipolar disorders (25, 41, 51). Third,
an increasing number of non-B HIV-1 subtype infections are
currently diagnosed. Here, we have shown that, in addition to
the prototypical subtype B LTR, the LTRs from subtypes A
through G of the HIV-1 group M were also activated syner-
gistically by TSA and TNF, and the amplitude of the synergism
correlated with the number of B sites in the respective LTRs,
which varies from one (subtype E) to three (subtype C). Based
on our results, we propose the administration of deacetylase
inhibitor(s) together with continuous HAART as a new poten-
tial therapeutic perspective to decrease in a subtype-nonspe-
cific manner the pool of latent HIV reservoirs.
In conclusion, the results described in this study provide new
insights into HIV-1 transcriptional regulation and more gen-
erally into the molecular mechanisms of NF-B-mediated
transactivation.
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